NR1H4 and liver disorder: Here, through high-throughput screening and subsequent biological evaluation, this study identifies 2-oxokolavenol as a novel FXR agonist with therapeutic potential in treating APAP-induced hepatocyte damage, providing a promising hit compound for the future development of FXR-selective modulators with therapeutic potential in treating liver diseases.